Celgene Co. (CELG) Shares Bought by Bank Hapoalim BM

Bank Hapoalim BM lifted its position in Celgene Co. (NASDAQ:CELG) by 322.4% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 7,653 shares of the biopharmaceutical company’s stock after acquiring an additional 5,841 shares during the quarter. Bank Hapoalim BM’s holdings in Celgene were worth $1,116,000 as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of CELG. Thompson Davis & CO. Inc. lifted its position in Celgene by 5.9% in the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 43 shares in the last quarter. Arcadia Investment Management Corp MI lifted its position in Celgene by 118.7% in the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 400 shares in the last quarter. Guidant Wealth Advisors purchased a new stake in Celgene in the 3rd quarter worth approximately $119,000. Motco lifted its position in Celgene by 19.3% in the 2nd quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 159 shares in the last quarter. Finally, Penserra Capital Management LLC purchased a new stake in Celgene in the 2nd quarter worth approximately $129,000. Institutional investors and hedge funds own 79.74% of the company’s stock.

Celgene Co. (NASDAQ CELG) opened at $106.00 on Friday. Celgene Co. has a 12 month low of $94.55 and a 12 month high of $147.17. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31. The stock has a market cap of $83,460.00, a price-to-earnings ratio of 25.00, a P/E/G ratio of 0.67 and a beta of 1.77.

Celgene (NASDAQ:CELG) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.87 by $0.04. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The business had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. During the same period last year, the business posted $1.58 EPS. Celgene’s revenue was up 10.2% compared to the same quarter last year. equities analysts anticipate that Celgene Co. will post 6.69 earnings per share for the current fiscal year.

A number of research firms have issued reports on CELG. Stifel Nicolaus set a $130.00 target price on shares of Celgene and gave the stock a “buy” rating in a research report on Monday, January 8th. SunTrust Banks set a $127.00 target price on shares of Celgene and gave the stock a “buy” rating in a research report on Monday, January 8th. Guggenheim reiterated a “buy” rating and issued a $147.00 target price on shares of Celgene in a research report on Wednesday. Oppenheimer set a $166.00 target price on shares of Celgene and gave the stock a “buy” rating in a research report on Monday, January 8th. Finally, Cantor Fitzgerald set a $112.00 target price on shares of Celgene and gave the stock a “hold” rating in a research report on Monday, January 8th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and nineteen have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $131.18.

TRADEMARK VIOLATION WARNING: “Celgene Co. (CELG) Shares Bought by Bank Hapoalim BM” was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.com-unik.info/2018/01/14/celgene-co-celg-shares-bought-by-bank-hapoalim-bm.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit